Venlafaxine

Generic Name: Venlafaxine

Brand Names: Effexor

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₇NO_₂

CAS Number: 93413-69-5

Unique Ingredient Identifier: GRZ5RCB1QG

Background: Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...

Indication: Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.

Associated Conditions: Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Associated Therapies: -

Clinical Trials

Serotonin Effect in Functional Dyspepsia

Not Applicable

Completed

Conditions: Dyspepsia

First Posted Date: 2005-06-22

Last Posted Date: 2007-09-24

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 300

Registration Number: NCT00115362

Locations: 🇳🇱
Canisius-Wilhelmina Hospital, Nijmegen, Netherlands
🇳🇱
Rijnstate Hospital, Arnhem, Netherlands
🇳🇱
Radboud University Nijmegen Medical Center, Nijmegen, P.O. Box 9101, Netherlands

and more 3 locations

Study of Antidepressants in Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson Disease
Depression

Interventions: Other: placebo
Drug: paroxetine
Drug: venlafaxine

First Posted Date: 2004-06-29

Last Posted Date: 2013-01-04

Lead Sponsor: University of Rochester

Target Recruit Count: 115

Registration Number: NCT00086190

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 15 locations

Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Hot Flashes
Sleep Disorders

First Posted Date: 2004-06-11

Last Posted Date: 2010-04-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 119

Registration Number: NCT00084669

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Treatment of Adolescent Suicide Attempters (TASA)

Phase 2

Completed

Conditions: Suicide, Attempted
Depression

First Posted Date: 2004-03-26

Last Posted Date: 2020-06-22

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 120

Registration Number: NCT00080158

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸
New York University Child Study Center, New York, New York, United States

and more 3 locations

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

Phase 3

Completed

Conditions: Hot Flashes

Interventions: Drug: medroxyprogesterone
Drug: venlafaxine

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 227

Registration Number: NCT00030914

Locations: 🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Coborn Cancer Center, Saint Cloud, Minnesota, United States
🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

and more 19 locations

Optimizing Electroconvulsive Therapy for Depression

Phase 4

Completed

Conditions: Depression
Depressive Disorder
Bipolar Disorder

Interventions: Procedure: High dosage electroconvulsive therapy
Drug: Nortriptyline
Drug: Venlafaxine
Drug: Lithium
Procedure: Low dosage electroconvulsive therapy

First Posted Date: 2002-09-17

Last Posted Date: 2013-08-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 340

Registration Number: NCT00045916

Locations: 🇺🇸
Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
🇺🇸
New York State Psychiatric Institute at Columbia University, New York, New York, United States
🇺🇸
Wake Forest University, Winston-Salem, North Carolina, United States

and more 1 locations

Treatments for Depression: Drug Versus Psychotherapy

Phase 3

Completed

Conditions: Depression

Interventions: Drug: Sertraline
Drug: Pill Placebo
Behavioral: Supportive Expressive Therapy
Drug: Venlafaxine

First Posted Date: 2002-08-12

Last Posted Date: 2017-06-02

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 156

Registration Number: NCT00043550

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

Phase 2

Completed

Conditions: Depression

Interventions: Drug: Fluoxetine
Drug: Venlafaxine
Behavioral: Cognitive Behavioral Therapy (CBT)
Drug: Citalopram

First Posted Date: 2001-07-12

Last Posted Date: 2014-03-12

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 334

Registration Number: NCT00018902

Locations: 🇺🇸
Kaiser Permanente Center for Health Research, Portland, Oregon, United States
🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
Brown University, Providence, Rhode Island, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy